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Atrogin-1 is required for optimal transcriptional activity of Forkhead 
























To determine whether endogenous atrogin-1  is  required  for 
Figure 1
Overexpression of atrogin-1 represses insulin- and IGF-1–induced car-
diomyocyte hypertrophy and Foxo1 and Foxo3a dephosphorylation. 
(A) Cardiomyocytes were infected with Ad-GFP or Ad–atrogin-1–GFP 
(MOI 10), and cells were stimulated with insulin (20 μg/ml–1), IGF-1 (20 
ng/ml–1), or PE (100 μM) for 24 h and stained with α-actinin antibody 
(red). Quantitation of cell surface area was performed on 100 cells 
per group. *P < 0.001 vs. serum-free control and Ad-GFP. (B) Protein 
levels of endogenous Akt pathway members were determined in car-
diomyocytes expressing atrogin-1 ectopically by IB with the indicated 
antibodies. (C) Foxo1 and Foxo3a expression and phosphorylation in 
cytoplasmic and nuclear fractions from cardiomyocytes were assessed 
by IB using anti-total or –phospho-Foxo1 and -Foxo3a antibodies after 
the indicated treatments. *P < 0.001 vs. Ad-GFP + insulin or IGF-1; 
#P < 0.01 vs. Ad-GFP + IGF-1. (D) Cardiomyocytes were infected with 
increasing MOIs of Ad–atrogin-1–GFP and Ad-GFP with IGF-1 (20 μg/ml–1) 
stimulation for 24 h. Endogenous Foxo1 and Foxo3a levels were 
determined by IB with the indicated antibodies. Maximal suppression 
of Foxo1 and Foxo3a occurred at MOI 30. *P < 0.001 vs. Ad-GFP + 
IGF-1 at MOI 30. (E) Cardiomyocytes were infected with Ad-siRNA–
control or Ad-siRNA–atrogin-1 and treated with insulin (20 μg/ml–1) 
or PE (100 μM) for 24 h. (F) Cardiomyocytes treated as indicated 
were stained with α-actinin antibody. Quantitation of cell surface area 
was performed on 100 cells per group. Original magnification, ×200. 
*P < 0.01 vs. Ad-siRNA control + insulin or PE. Scale bars: 50 μm.
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Figure 2
Atrogin-1 interacts with Foxo1 and Foxo3a in vivo and in vitro. (A) We transfected 293 cells with the indicated plasmids. Equal amounts of protein 
lysates were immunoprecipitated with anti-HA or anti-Myc antibody and analyzed by IB with the indicated antibodies. WCE, whole cell extract. (B) 
The ability of Foxo1 and Foxo3a expressed in 293 cells to be retained by GST or a GST–atrogin-1 fusion protein was analyzed by IB after GST 
pulldown. (C) Endogenous protein interactions were examined in cardiomyocyte cell lysates immunoprecipitated with rabbit IgG or anti–atrogin-1 
antibody and analyzed by IB with antibodies to detect Foxo1, Foxo3a, and atrogin-1. (D) Domains of atrogin-1 involved in binding to Foxo1 and 
Foxo3a expressed in 293 cells were mapped with GST pulldown assays. GST–atrogin-1 proteins were affinity purified and analyzed by SDS-
PAGE and Coomassie blue staining. The ability of the truncated atrogin-1 fusion proteins to bind to Foxo1 and Foxo3a from whole-cell lysates 
was determined by blotting with antibodies against Flag and HA, respectively. (E) Deletion constructs of atrogin-1 in D that bind to Foxo1 and 
Foxo3a. NLS, nuclear localization sequence; PDZ, PDZ-binding domain. (F) Interaction domains of Foxo1 required for binding to atrogin-1 were 
mapped by co-IP. We transfected 293 cells with the indicated Flag-Foxo1 and HA–atrogin-1 plasmids. Equal amounts of lysates were prepared 
for IP with a Flag antibody and immunoblotted with antibodies for HA or Flag. (G) Deletion constructs of Foxo1 in F that bind to atrogin-1. FK, 
Forkhead domain; NES, nuclear export sequence; LxxLL, nuclear receptor–interacting domain or LxxLL motif; TAD, transactivation domain.
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Atrogin-1 induces Foxo1 and Foxo3a nuclear localization and increased transcriptional activity. (A) Cardiomyocytes were transiently transfected 
with expression vectors encoding HA-Foxo3a or Myc–atrogin-1. At 24 h after transfection, cells were treated without or with insulin for 12 h 
and immunostained with antibodies against HA (green) and Myc (red). Staining was assessed by confocal microscopy; representative images 
are shown. Scale bars: 50 μm. (B) Cardiomyocytes (100 random cells per condition) expressing the indicated proteins were scored for Foxo1 
or Foxo3a localization. Data are mean ± SEM of 2 independent experiments. Original magnification, ×200. (C) To assess the role of atrogin-1 
on Foxo3a-dependent transcription, cardiomyocytes were transfected with luciferase expression plasmids driven by the indicated promoters 
and vectors expressing Foxo3a or Foxo3aA3 (a constitutively active form) and atrogin-1. Data were normalized by cotransfection with a plas-
mid expressing β-gal. Cells were harvested 24 h later for measurement of luciferase activities. Results are expressed relative to the level of 
expression with the reporter gene alone and representative of 3 independent experiments. Error bars indicate SEM. (D) Cardiomyocytes were 
transfected with a luciferase reporter driven by the p27kip1 promoter along with Foxo1 or Foxo3a and plasmids expressing siRNA–atrogin-1 or 
siRNA-control. Luciferase activity was measured 24 h after transfection. *P < 0.01 vs. control siRNA.
research article
3216	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 117      Number 11      November 2007
Figure 4
Atrogin-1 induces lysine 63–dependent ubiquitylation of Foxo3a. (A) Cultured 293 cells were transfected with the indicated plasmids, and pulse-
chase analysis was performed. Extracts were subjected to IP using either anti-Flag or anti-HA antibodies. Immunoprecipitates were analyzed 
by SDS−PAGE followed by autoradiography. (B) The indicated plasmids were cotransfected, and 293 cells were treated for 4 h with DMSO or 
MG132 (20 μM). The expression levels of the respective proteins were analyzed by IB with anti-Flag, anti-HA, or anti-Myc antibodies. (C) We 
transfected 293 cells with vectors expressing HA-ubiquitin (HA-Ub), HA-Foxo3a, atrogin-1, or atrogin-1 ΔF-box mutant lacking the E3-ligase 
activity. Cell extracts were immunoprecipitated with Foxo3a antibody and analyzed by IB with the indicated antibodies. An aliquot of the cell 
extracts was subjected to direct IB analysis using anti-Foxo3a or anti-Myc antibodies. (D) In vitro ubiquitylation reactions were performed with 
purified ubiquitin, E1, the E2 UBC13, GST-Foxo3a, and the SCFatrogin-1 complex. Reactions were resolved by SDS-PAGE followed by IB with 
anti-ubiquitin antibody. (E) We cotransfected 293 cells with the indicated plasmids. At 24 h after transfection, ubiquitin-conjugated proteins were 
prepared for IP with anti-Foxo3a. Immunoprecipitates were subject to SDS−PAGE followed by IB with anti-ubiquitin, anti-Foxo3a, or anti-Myc 
antibodies. An aliquot of the cell extracts was subjected to direct IB analysis using anti-Foxo3a or anti-Myc antibodies.
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Lysine 63–linked ubiquitin chains are 
required for transcriptional coactivation of 
Foxo3a by atrogin-1. (A) Cultured cardio-
myocytes were transfected with vectors 
expressing HA-Foxo3a, Myc–atrogin-1, and/
or atrogin-1 ΔF-box together with the p27kip1 
luciferase reporter and β-gal constructs. At 
24 h after transfection, cells were lysed and 
luciferase activity was measured. Lysates 
were immunoblotted with anti-HA and Myc. 
*P < 0.01 vs. atrogin-1 WT. (B) We trans-
fected 293 cells with the indicated plasmids. 
Equal amounts of protein lysates were 
immunoprecipitated with anti-Myc or anti-HA 
antibodies to detect atrogin-1 and Foxo3a, 
respectively, followed by IB to detect protein-
protein interactions. (C) Reporter assays 
were performed using the p27kip1 promoter in 
cardiomyocytes cotransfected with plasmids 
expressing Foxo3a and/or atrogin-1, along 
with vectors expressing WT ubiquitin or 
mutant ubiquitins containing mutations of 
lysine 48 (K48R) or lysine 63 (K63R). At 24 
h after transfection, cells were lysed and 
luciferase activity was measured. Lysates 
were immunoblotted with anti-HA and Myc. 
*P < 0.001 vs. WT ubiquitin. Results are 
expressed relative to the level of expression 
with the reporter gene alone and represen-
tative of 3 independent experiments. Error 
bars indicate SEM.
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effects of atrogin-1 on the Fork-














bly.  If  this  model  is  true,  then 
prevention  of  lysine  63–linked 














effects  of  atrogin-1,  whereas 
lysine 48–ubiquitin had no effect 
(Figure 5C). Similar results were 


















Atrogin-1 increases Forkhead pro-
tein activity and suppresses IGF-1– 
dependent cardiac hypertrophy in 
vivo. To test the relevance of our 





Enhanced Forkhead protein ubiquitylation and activity and suppressed IGF-1/GH-dependent cardiac 
hypertrophy in cardiac-specific atrogin-1 Tg mice. (A) Cardiac hypertrophy was induced in 8-wk-old mice 
with IGF-1/GH injections. Atrogin-1 Tg and WT mice were sacrificed 14 d later; their hearts were freshly 
isolated; and levels of the indicated total and phospho-proteins were determined by IB. Results were 
normalized to relative expression levels of phospho-Foxo1, Foxo3a, and Akt (n = 6). *P < 0.001 vs. WT. 
(B) Equal amounts of lysates from WT and Tg hearts were immunoprecipitated with Foxo3a antibody and 
analyzed by IB with antibodies against ubiquitin or Foxo3a to detect ubiquitylated forms of Foxo3a in vivo 
before and after IGF-1/GH treatment. (C) RT-PCR was performed to measure the expression of known 
Foxo1 and Foxo3a target genes in WT and Tg mouse hearts before and after IGF-1/GH treatment. Total 
RNA was isolated from mouse hearts, and expression of transcripts for Bim, p27Kip1, GADD45, SOD2, 
and GAPDH was determined and normalized to GAPDH (n = 6). *P < 0.001 vs. WT. A representative 
analysis is shown. (D) M-mode echocardiographic analysis of hearts from Tg and WT mice after 2 wk 
IGF-1/GH injection. (E) Representative macroscopic histologic analysis of H&E-stained hearts from indi-
cated mice after 2 wk IGF-1/GH injection. Histologic sections were also stained with wheat germ aggluti-
nin–TRITC conjugate to determine cell size. Scale bars: 1 mm (top); 50 μm (bottom). (F) Cardiomyocyte 
size from WT and Tg hearts after IGF-1/GH treatment.
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Echocardiography of dimensions and function in WT and atrogin-1 Tg mice  
at baseline and after 2 wk IGF/GH treatment
	 WT	baseline	 Tg	baseline	 WT	2	wk	 Tg	2	wk
BW (g) 19.2 ± 2.3 23.8 ± 1.7 24.9 ± 3.4 27.9 ± 1.5
HW/TL (mg/mm) ND ND 8.66 ± 0.31 7.49 ± 0.35
LV mass index (mg) 109.9 ± 11.5 113.8 ± 5.5 158.1 ± 12.3A 133.5 ± 6.9A,B
HR (bpm) 675.77 ± 23.02 640.8 ± 24.15 699.12 ± 17.39 676.83 ± 10.67
IVSTD (mm) 0.93 ± 0.06 0.90 ± 0.05 1.24 ± 0.06A 1.01 ± 0.05A,B
IVSTS (mm) 1.58 ± 0.09 1.62 ± 0.05 1.85 ± 0.09A 1.64 ± 0.05B
PWTD (mm) 1.01 ± 0.05 1.00 ± 0.03 1.10 ± 0.05A 0.95 ± 0.04A,B
PWTS (mm) 1.50 ± 0.07 1.48 ± 0.05 1.70 ± 0.06A 1.50 ± 0.03B
LVEDD (mm) 3.2 ± 0.17 3.37 ± 0.10 3.25 ± 0.10 3.6 ± 0.13A,B
LVESD (mm) 1.60 ± 0.1 1.66 ± 0.7 1.49 ± 0.08 1.72 ± 0.09
FS (%) 50.17±1.03 50.85 ± 1.50 54.13 ± 1.64 52.20 ± 1.99
Transthoracic echocardiography on unanesthetized mice. Data are mean ± SEM. BW, body 
wt; HW/TL, heart wt/tibia length; HR, heart rate; IVSTD, interventricular septal thickness in 
diastole; IVSTS, interventricular septal thickness in systole; PWTD, posterior wall thickness 
in diastole; PWTS, posterior wall thickness in systole; LVEDD, LV end-diastolic dimension; 
LVESD, LV end-systolic dimension; ND, not determined. LV mass index was calculated as 
(external LV diameter in diastole3 – LV end-diastolic dimension3) x 1.055. Fractional shorten-
ing (FS) was calculated as (LV end-diastolic dimension – LV end-systolic dimension)/LV end-
diastolic dimension. AP < 0.001 vs. baseline. BP < 0.001 vs. WT 2 wk.
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Lack of atrogin-1 expression results in exagger-
ated cardiac hypertrophy in response to voluntary 
running exercise. (A) Representative macroscopic 
histologic analysis of H&E-stained mouse hearts 
after 3 wk voluntary wheel exercise. Scale bar: 1 
mm. Histologic sections were also stained with 
wheat germ agglutinin-TRITC to determine cell 
size. Scale bars: 1 mm (top); 50 μm (bottom). (B) 
Quantitation of cardiomyocyte size from WT and 
Atrogin-1–/– heart after 3 wk voluntary wheel exer-
cise and sham controls. (C) M-mode echocardio-
graphic analysis of hearts from WT and Atrogin-1–/– 
mice after 3 wk voluntary wheel exercise.
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In vitro ubiquitylation reactions. For atrogin-1–mediated ubiquitylation, 
Skp1, Cul1, and Roc1 immunocomplexes were precipitated from trans-
Table 2
Echocardiography and run statistics of Atrogin-1–/– and littermate Atrogin-1+/+ mice at baseline and after 3 wk voluntary running
	 WT	baseline	 Atrogin-1–/–	baseline	 WT	3	wk	running	 Atrogin-1–/–	3	wk	running	 Atrogin-1–/–	3	wk	sham
Run time/24 h (h) ND ND 4.45 ± 0.52 4.63 ± 0.60 0
Distance/24 h (miles) ND ND 1.89 ± 0.35 1.80 ± 0.35 0
Speed (MPH) ND ND 0.35 ± 0.28 0.36 ± 0.17 0
BW (g) 22.9 ± 0.9 23.3 ± 1.2 23.5 ± 0.7 23.0 ± 0.6 22.3 ± 1.3
HW/TL (mg/mm) ND ND 7.4 ± 0.5 8.2 ± 0.5A,B 7.1 ± 0.5
LV mass index (mg) 95.4 ± 11.2 98.4 ± 5.4 127.4 ± 6.8C 153.1 ± 8.0A,B,C 97.0 ± 3.3
HR (bpm) 638.1 ± 23 625.1 ± 19 654 ± 21 630 ± 17 633 ± 24
IVSTD (mm) 0.87 ± 0.01 0.87 ± 0.02 1.04 ± 0.01C 1.24 ± 0.03A,B,C 0.86 ± 0.01
IVSTS (mm) 1.51 ± 0.05 1.51 ± 0.05 1.7 ± 0.02C 1.89 ± 0.16A,B,C 1.51 ± 0.14
PWTD (mm) 0.86 ± 0.03 0.86 ± 0.02 0.97 ± 0.04C 1.25 ± 0.05A,B,C 0.82 ± 0.01
PWTS (mm) 1.53 ± 0.06 1.52 ± 0.05 1.57 ± 0.04C 1.7 ± 0.05A,B,C 1.48 ± 0.06
LVEDD (mm) 2.95 ± 0.15 3.17 ± 0.08 3.17 ± 0.10 2.86 ± 0.12 3.17 ± 0.06
LVESD (mm) 1.31 ± 0.06 1.42 ± 0.06 1.34 ± 0.04 1.23 ± 0.10 1.47 ± 0.07
FS% 54.1 ± 2.4 53.4 ± 1.2 55.6 ± 0.9 55.2 ± 2.1 52.5 ± 2.4
Transthoracic echocardiography on unanesthetized mice. Data are mean ± SEM. MPH, miles per h; BW, body wt; HW/TL, heart wt/tibia length; HR, heart rate; 
IVSTD, interventricular septal thickness in diastole; IVSTS, interventricular septal thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, pos-
terior wall thickness in systole; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic dimension; ND, not determined.LV mass index was calculated as 
(external LV diameter in diastole3 – LV end-diastolic dimension3) x 1.055. Fractional shortening (FS) was calculated as (LV end-diastolic dimension – LV end-
systolic dimension)/LV end-diastolic dimension. AP < 0.001 vs. WT 3 wk running. BP < 0.01 vs. Atrogin-1–/– 3 wk sham. CP < 0.01 vs. baseline.
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